JPWO2021007338A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021007338A5 JPWO2021007338A5 JP2022500004A JP2022500004A JPWO2021007338A5 JP WO2021007338 A5 JPWO2021007338 A5 JP WO2021007338A5 JP 2022500004 A JP2022500004 A JP 2022500004A JP 2022500004 A JP2022500004 A JP 2022500004A JP WO2021007338 A5 JPWO2021007338 A5 JP WO2021007338A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- chain variable
- variable region
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 238000002405 diagnostic procedure Methods 0.000 claims 5
- 208000019423 liver disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025052993A JP2025111457A (ja) | 2019-07-08 | 2025-03-27 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962871565P | 2019-07-08 | 2019-07-08 | |
| US62/871,565 | 2019-07-08 | ||
| PCT/US2020/041228 WO2021007338A1 (en) | 2019-07-08 | 2020-07-08 | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025052993A Division JP2025111457A (ja) | 2019-07-08 | 2025-03-27 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022540079A JP2022540079A (ja) | 2022-09-14 |
| JP2022540079A5 JP2022540079A5 (https=) | 2023-07-18 |
| JPWO2021007338A5 true JPWO2021007338A5 (https=) | 2023-07-18 |
| JP7658946B2 JP7658946B2 (ja) | 2025-04-08 |
Family
ID=71944318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500004A Active JP7658946B2 (ja) | 2019-07-08 | 2020-07-08 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
| JP2025052993A Pending JP2025111457A (ja) | 2019-07-08 | 2025-03-27 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025052993A Pending JP2025111457A (ja) | 2019-07-08 | 2025-03-27 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12377162B2 (https=) |
| EP (1) | EP3996816A1 (https=) |
| JP (2) | JP7658946B2 (https=) |
| CN (2) | CN114174341A (https=) |
| CA (1) | CA3145301A1 (https=) |
| WO (1) | WO2021007338A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112292401A (zh) | 2018-03-06 | 2021-01-29 | 英凯尔生物科技有限责任公司 | 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 |
| EP3996816A1 (en) | 2019-07-08 | 2022-05-18 | Imcare Biotech, LLC | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
| WO2021050217A1 (en) * | 2019-09-11 | 2021-03-18 | Imcare Biotech, Llc. | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| US20250369960A1 (en) * | 2022-06-30 | 2025-12-04 | Allonnia, Llc | Per- and polyfluorinated alkyl compound (pfas) binding proteins and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| KR100332254B1 (ko) | 1993-10-01 | 2002-09-27 | 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 | 신규인펩티드유도체 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2007030560A2 (en) | 2005-09-08 | 2007-03-15 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents |
| CA2703140A1 (en) | 2007-10-25 | 2009-04-30 | Viventia Biotech Inc. | Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| US20110206697A1 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Spink1 targeted therapy |
| US20140308657A1 (en) * | 2010-12-09 | 2014-10-16 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Serine protease inhibitor kazal antibodies |
| CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| WO2014127200A1 (en) | 2013-02-15 | 2014-08-21 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| AU2017239637A1 (en) | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| EP4219559A3 (en) | 2017-12-22 | 2023-10-18 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| CN112292401A (zh) | 2018-03-06 | 2021-01-29 | 英凯尔生物科技有限责任公司 | 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 |
| CN109678950B (zh) | 2019-01-08 | 2022-05-10 | 灏灵赛奥（天津）生物科技有限公司 | spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品 |
| EP3996816A1 (en) | 2019-07-08 | 2022-05-18 | Imcare Biotech, LLC | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
| WO2021050217A1 (en) * | 2019-09-11 | 2021-03-18 | Imcare Biotech, Llc. | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| MX2022012752A (es) | 2020-04-15 | 2023-01-16 | Voyager Therapeutics Inc | Compuestos de union a tau. |
-
2020
- 2020-07-08 EP EP20750919.1A patent/EP3996816A1/en active Pending
- 2020-07-08 CA CA3145301A patent/CA3145301A1/en active Pending
- 2020-07-08 CN CN202080054708.9A patent/CN114174341A/zh active Pending
- 2020-07-08 CN CN202510175468.2A patent/CN119874926A/zh active Pending
- 2020-07-08 JP JP2022500004A patent/JP7658946B2/ja active Active
- 2020-07-08 WO PCT/US2020/041228 patent/WO2021007338A1/en not_active Ceased
- 2020-07-08 US US17/625,693 patent/US12377162B2/en active Active
-
2025
- 2025-03-27 JP JP2025052993A patent/JP2025111457A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025111457A5 (https=) | ||
| JP2023153895A5 (https=) | ||
| JP2021105034A5 (https=) | ||
| JP2020522261A5 (https=) | ||
| JP2009541204A5 (https=) | ||
| JP2020534830A5 (https=) | ||
| JP2020526478A5 (https=) | ||
| JP2021500916A5 (https=) | ||
| JP2020516603A5 (https=) | ||
| JP2015527365A5 (https=) | ||
| JP2015531768A5 (https=) | ||
| JP2016505634A5 (https=) | ||
| JP2015502752A5 (https=) | ||
| JP2015527368A5 (https=) | ||
| RU2011121818A (ru) | Способ иммунологического анализа белка cxcl1 человека | |
| JP2018525320A5 (https=) | ||
| JP2018515071A5 (https=) | ||
| JP2021515597A5 (https=) | ||
| EP3983806A1 (en) | Multiplex competition assay for profiling binding epitopes of affinity agents for clinical diagnostics use | |
| JP2020189843A5 (https=) | ||
| JP2021155416A5 (https=) | ||
| JPWO2021007338A5 (https=) | ||
| JP5821198B2 (ja) | 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法 | |
| RU2019132201A (ru) | Антитела к человеческому эритроферрону и их применение | |
| JPWO2020190737A5 (https=) |